Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-13
2007-03-13
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
10776002
ABSTRACT:
This invention pertains to compounds of Formula I:and all pharmaceutically-acceptable forms thereof.The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein.The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound or salt of the invention to decrease the symptoms or slow the progression of these diseases or disorders.The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an disease or disorder responsive to EphB4modulation.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent.The invention also includes a method for determining the presence of EphB4kinase in a sample, comprising contacting the sample with a compound of Formula I, or form thereof, and the detecting the amount of compound or form bound to EphB4kinase, and therefrom determining the presence or absence of EphB4kinase in the sample.
REFERENCES:
patent: 5593997 (1997-01-01), Dow et al.
patent: 5658857 (1997-08-01), Andree et al.
patent: 5783576 (1998-07-01), Roos et al.
patent: 6919341 (2005-07-01), Paruch et al.
patent: 2003/0212073 (2003-11-01), Currie et al.
patent: 2004/0063715 (2004-04-01), Paruch et al.
patent: 2004/0067951 (2004-04-01), DeSimone et al.
patent: 2004/0072835 (2004-04-01), Paruch et al.
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 2005/0009832 (2005-01-01), Sun et al.
patent: 2005/0054649 (2005-03-01), Currie et al.
patent: 2005/0085484 (2005-04-01), Mitchell et al.
patent: 2005/0090499 (2005-04-01), Currie et al.
patent: 2005/0101604 (2005-05-01), Currie et al.
patent: 2005/0288295 (2005-12-01), Currie et al.
patent: 43 37 609 (1995-05-01), None
patent: 0 480 713 (1992-04-01), None
patent: WO 88/04298 (1988-06-01), None
patent: WO 95/12594 (1995-05-01), None
patent: WO 96/04298 (1996-02-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 99/28322 (1999-06-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 02/10170 (2002-02-01), None
patent: WO 02/30428 (2002-04-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/066481 (2002-08-01), None
patent: WO 02/076985 (2002-10-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 2003/089434 (2003-10-01), None
patent: WO 2004/022562 (2004-03-01), None
patent: WO 2004/026310 (2004-04-01), None
patent: WO 2004/026877 (2004-04-01), None
patent: WO 2004/072080 (2004-08-01), None
patent: WO 2004/072081 (2004-08-01), None
patent: WO 2005/005429 (2005-01-01), None
patent: WO 2005/014599 (2005-02-01), None
patent: WO 2005/019220 (2005-03-01), None
patent: WO 2005/047290 (2005-05-01), None
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Jeffery, Trina K., et al., “Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: DIfferences Between Early and Established Pulmonary Hypertension” Journal of Cardiovascular Pharmacology 1998, vol. 32, No. 2, pp. 213-219.
Hanks, Steven K., “Hanks Classification” 1994, pp. 1-4 http://pkr.sdsc.edu/html/pk—catalytic/pk—hanks—class.html.
Lumma, William C., et al., “Piperazinylimidazo {1,2-a]pyrazines with Selective Affinity for in Vitro—-Adrenergic Receptor Subtypes” J. Med. Chem. 1983, vol. 26, pp. 357-363.
Stenberg, Kaj A. E., et al., “KinMutBase, a database of human disease-causing protein kinase mutations” Nucleic Acids Research 2000, vol. 28, pp. 369-372.
Vitse, O. et al., “New Imidazo[1,2-a]pyrazine Derivatives with Bronchodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities” Bioorganic & Medicinal Chemistry 1999, vol. 7, pp. 1059-1065.
Ding et al. (2002) “A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries,” J. Am. Chem. Soc., 124(8): 1594-1596.
Office Action dated May 24, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004.
“Protein Kinases in Disease,” references produced from a Sep. 24, 1997, search of the On-line Meddelian Inheritance in Man (OMIM) database, pp. 1-11, from http://bioinformatics.weizmann.ac.il/Kinases/pkr/pk—medicine.html.
International Search Report dated Oct. 22, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Written Opinion dated Dec. 5, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Second Written Opinion dated Apr. 13, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Preliminary Examination Report dated Aug. 3, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Search Report dated Feb. 9, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
Written Opinion dated Jul. 6, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Preliminary Examination Report dated Oct. 27, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003922, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003923, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Dec. 8, 2004, for Application No. PCT/US2004/021150, International filing date Jun. 30, 2004.
International Search Report and Written Opinion dated Dec. 30, 2004, for Application No. PCT/US2004/018227, International filing date Jun. 4, 2004.
International Search Report and Written Opinion dated Feb. 1, 2005, for Application No. PCT/US2004/025884, International filing date Aug. 11, 2004.
Invitation to Pay Additional Fees with Partial International Search Report dated May 3, 2005, for Application No. PCT/US2004/037433, International filing date Nov. 10, 2004.
International Search Report and Written Opinion dated Jun. 23, 2005, for Application No. PCT/US2004/037433, International filing date Nov. 10, 2004.
Currie Kevin S.
DeSimone Robert W.
Mitchell Scott A.
Pippin Douglas A.
CGI Pharmaceuticals, Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Tucker Zachary C.
LandOfFree
Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3721644